- Home
- QURE vs CIM Comparison
QURE vs CIM Comparison
Compare QURE & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | CIM |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | QURE | CIM |
|---|---|---|
| Price | $17.61 | $13.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 2 |
| Target Price | ★ $44.92 | $15.25 |
| AVG Volume (30 Days) | ★ 1.6M | 789.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.08% |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $126.12 | $1.80 |
| Revenue Next Year | $200.43 | $2.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $10.99 |
| 52 Week High | $71.50 | $14.88 |
Technical Indicators
Market Signals| Indicator | QURE | CIM |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 61.07 |
| Support Level | $13.47 | $12.96 |
| Resistance Level | $18.37 | $14.10 |
| Average True Range (ATR) | 1.33 | 0.28 |
| MACD | 0.27 | 0.10 |
| Stochastic Oscillator | 87.86 | 96.55 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.